Similar to DLBCL and STAD, patients with THYM demonstrated higher levels of PSMD3 mRNA expression compared with normal controls, despite lower levels correlating with worse outcomes (Figure S2C). This evidence concerns the gene PSMD3 and gastric adenocarcinoma.